Narendra Varde
Managing Director, Roche Diagnostics India & Neighboring Markets
As a leader in diagnostics testing, we have a responsibility to deliver effective solutions for patients fast. Testing is a critical part in fighting this unprecedented global healthcare emergency and we are proud to be able to contribute.
After having launched a PCR test to detect Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19 and a SARS CoV-2 antibody test that detects antibodies, we have been diligently and urgently working to bring more reliable immunoassay solution to the market.
The cobas® SARS-CoV-2 Test is a real-time RT-PCR test intended for the qualitative detection of nucleic acids from SARS-CoV-2 in nasal, nasopharyngeal, and oropharyngeal swab samples from patients.
Both tests can run on Roche’s fully automated cobas® 6800 and cobas® 8800 Systems.
Disclaimer:
FDA-Emergency Use Authorisation, CE-IVD
India CDSCO approval issued due to an emergency health situation in the public interest.
Elecsys® Anti-SARS-CoV-2 is an immunoassay for the in vitro qualitative detection of antibodies (including IgG) to SARS-CoV-2 in human serum and plasma. The test is intended as an aid in the determination of the immune reaction to SARS-CoV-2.
Elecsys® Anti-SARS-CoV-2 S is an immunoassay for the in vitro quantitative determination of antibodies (including IgG) to the SARS-CoV-2 spike (S) protein receptor binding domain (RBD) in human serum and plasma. The test is intended as an aid to assess the adaptive humoral immune response to the SARS‑CoV‑2 S protein.
The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers.
Reliable diagnostic tests targeting patients that are currently infected by the virus, as well as those that have an immune response against the virus, are valuable. However, it is important to understancd which tests are most suitable to use depending on their intended purpose.
* Uncontested proof of protective immunity in persons with antibodies against SARS-CoV-2 is pending. Data presented here are based on current scientific understanding of the disease (Jan 2021)
Watch this video which explains the different diagnostic tests available for SARS-CoV-2 and when they are most effectively used.
Abbreviations
COVID-19: coronavirus disease 2019
RT-PCR: reverse transcription polymerase chain reaction
